Eaddy, Michael; Seal, Brian; Tangirala, Krishna; … - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 431-440
Background: Rasburicase is a recombinant urate-oxidase enzyme used to reduce high levels of plasma uric acid (PUA) resulting from tumour lysis syndrome (TLS). Rasburicase reduces PUA levels within 4 hours of administration, thereby minimizing the risk of serious complications from TLS. Treatment...
